• Vaccine Name: DR2/DIMQ
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: The antigen is a fusion protein (DR2) composed of Rv0572c and Rv3621c from Mycobacterium tuberculosis (Mao et al., 2023).
• Rv0572c gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Mao et al., 2023).
  • Detailed Gene Information: Click Here.
• Rv3126c gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Mao et al., 2023).
  • Detailed Gene Information: Click Here.
• Preparation: The DR2 fusion protein is produced by combining Rv0572c and Rv3621c and is formulated with the DIMQ liposomal adjuvant (Mao et al., 2023).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Mice were first primed with BCG, followed by boost immunizations with the DR2/DIMQ vaccine at specific intervals. After vaccination, immune responses were assessed through cytokine production and memory T-cell analysis, and protection was evaluated against Mycobacterium tuberculosis(Mao et al., 2023).
• Challenge Protocol: Protective efficacy was evaluated using in vitro infection models with Mycobacterium tuberculosis (Mao et al., 2023).
• Efficacy: The vaccine demonstrated protective effects by inhibiting the growth of M. tuberculosis and enhancing immune protection compared to BCG alone (Mao et al., 2023).
• Information about this animal model: Mouse Model for TB research